The endogenous cannabinoid system protects against colonic inflammation.

Excessive inflammatory responses can emerge as a potential danger for organisms' health. Physiological balance between pro- and anti-inflammatory processes constitutes an important feature of responses against harmful events. Here, we show that cannabinoid receptors type 1 (CB1) mediate intrinsic protective signals that counteract proinflammatory responses. Both intrarectal infusion of 2,4-dinitrobenzene sulfonic acid (DNBS) and oral administration of dextrane sulfate sodium induced stronger inflammation in CB1-deficient mice (CB1(-/-)) than in wild-type littermates (CB1(+/+)). Treatment of wild-type mice with the specific CB1 antagonist N-(piperidino-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-pyrazole-3-carboxamide (SR141716A) mimicked the phenotype of CB1(-/-) mice, showing an acute requirement of CB1 receptors for protection from inflammation. Consistently, treatment with the cannabinoid receptor agonist R(-)-7-hydroxy-Delta(6)-tetra-hydrocannabinol-dimethylheptyl (HU210) or genetic ablation of the endocannabinoid-degrading enzyme fatty acid amide hydrolase (FAAH) resulted in protection against DNBS-induced colitis. Electrophysiological recordings from circular smooth muscle cells, performed 8 hours after DNBS treatment, revealed spontaneous oscillatory action potentials in CB1(-/-) but not in CB1(+/+) colons, indicating an early CB1-mediated control of inflammation-induced irritation of smooth muscle cells. DNBS treatment increased the percentage of myenteric neurons expressing CB1 receptors, suggesting an enhancement of cannabinoid signaling during colitis. Our results indicate that the endogenous cannabinoid system represents a promising therapeutic target for the treatment of intestinal disease conditions characterized by excessive inflammatory responses.

[1]  M. Storr,et al.  Structural differences in the enteric neural network in murine colon: impact on electrophysiology. , 2003, American journal of physiology. Gastrointestinal and liver physiology.

[2]  Darrell R. Abernethy,et al.  International Union of Pharmacology: Approaches to the Nomenclature of Voltage-Gated Ion Channels , 2003, Pharmacological Reviews.

[3]  D. Piomelli The molecular logic of endocannabinoid signalling , 2003, Nature Reviews Neuroscience.

[4]  R. Capasso,et al.  An endogenous cannabinoid tone attenuates cholera toxin-induced fluid accumulation in mice. , 2003, Gastroenterology.

[5]  C. Gaveriaux-Ruff,et al.  Anti-inflammatory properties of the mu opioid receptor support its use in the treatment of colon inflammation. , 2003, The Journal of clinical investigation.

[6]  D. R. Linden,et al.  Enhanced excitability of myenteric AH neurones in the inflamed guinea‐pig distal colon , 2003, The Journal of physiology.

[7]  R. Zurier Prospects for cannabinoids as anti‐inflammatory agents , 2003, Journal of cellular biochemistry.

[8]  A. Izzo,et al.  Cannabinoids for gastrointestinal diseases: potential therapeutic applications , 2003, Expert opinion on investigational drugs.

[9]  B. Cravatt,et al.  The enzymatic inactivation of the fatty acid amide class of signaling lipids. , 2002, Chemistry and physics of lipids.

[10]  M. Cascio,et al.  The endocannabinoid system and the molecular basis of paralytic ileus in mice , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[11]  W. Zieglgänsberger,et al.  The endogenous cannabinoid system controls extinction of aversive memories , 2002, Nature.

[12]  K. Mackie,et al.  Localisation of cannabinoid CB1 receptor immunoreactivity in the guinea pig and rat myenteric plexus , 2002, The Journal of comparative neurology.

[13]  G. Barbara,et al.  A role for inflammation in irritable bowel syndrome? , 2002, Gut.

[14]  T. Bisogno,et al.  Endocannabinoids as physiological regulators of colonic propulsion in mice. , 2002, Gastroenterology.

[15]  E. Mayer,et al.  Evolving pathophysiologic models of functional gastrointestinal disorders. , 2002, Gastroenterology.

[16]  M. Herkenham,et al.  International Union of Pharmacology. XXVII. Classification of Cannabinoid Receptors , 2002, Pharmacological Reviews.

[17]  G. Marsicano,et al.  Coexpression of the cannabinoid receptor type 1 with dopamine and serotonin receptors in distinct neuronal subpopulations of the adult mouse forebrain , 2002, Neuroscience.

[18]  A. Izzo,et al.  The gastrointestinal pharmacology of cannabinoids. , 2001, Current opinion in pharmacology.

[19]  G. Denhardt,et al.  The anti-inflammatory activities of cannabinoid receptor ligands in mouse peritonitis models. , 2001, European journal of pharmacology.

[20]  P. Holzer Gastrointestinal afferents as targets of novel drugs for the treatment of functional bowel disorders and visceral pain. , 2001, European journal of pharmacology.

[21]  R. Capasso,et al.  Cannabinoid CB1‐receptor mediated regulation of gastrointestinal motility in mice in a model of intestinal inflammation , 2001, British journal of pharmacology.

[22]  B. Cravatt,et al.  Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[23]  E. van Marck,et al.  Disturbance of the prejunctional modulation of cholinergic neurotransmission during chronic granulomatous inflammation of the mouse ileum , 2001, British journal of pharmacology.

[24]  R. Pertwee Cannabinoids and the gastrointestinal tract , 2001, Gut.

[25]  C. Kelly,et al.  Interleukin 16 is up-regulated in Crohn's disease and participates in TNBS colitis in mice. , 2000, Gastroenterology.

[26]  C. Probert,et al.  Mucins and inflammatory bowel disease , 2000, Postgraduate medical journal.

[27]  G. Marsicano,et al.  Expression of the cannabinoid receptor CB1 in distinct neuronal subpopulations in the adult mouse forebrain , 1999, The European journal of neuroscience.

[28]  Shea-Donohue,et al.  Progressive alterations in circular smooth muscle contractility in TNBS‐induced colitis in rats , 1999, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.

[29]  S. Collins,et al.  The role of CD4+ lymphocytes in the susceptibility of mice to stress-induced reactivation of experimental colitis , 1999, Nature Medicine.

[30]  P. Andrews,et al.  Fundamentals of neurogastroenterology , 1999, Gut.

[31]  J. Manzanares,et al.  Pharmacological and biochemical interactions between opioids and cannabinoids. , 1999, Trends in pharmacological sciences.

[32]  M. Elia Glutamine in parenteral nutrition: more food for thought , 1999, Gut.

[33]  S. Jaggar,et al.  The endogenous cannabinoid anandamide, but not the CB2 ligand palmitoylethanolamide, prevents the viscero-visceral hyper-reflexia associated with inflammation of the rat urinary bladder , 1998, Neuroscience Letters.

[34]  F. Borrelli,et al.  Excitatory transmission to the circular muscle of the guinea‐pig ileum: evidence for the involvement of cannabinoid CB1 receptors , 1998, British journal of pharmacology.

[35]  J. D. Richardson,et al.  Cannabinoids reduce hyperalgesia and inflammation via interaction with peripheral CB1 receptors , 1998, Pain.

[36]  H. Parkman,et al.  Acute experimental colitis decreases colonic circular smooth muscle contractility in rats. , 1997, American journal of physiology. Gastrointestinal and liver physiology.

[37]  S. Pyne,et al.  Sphingosine prevents diacylglycerol signaling to mitogen-activated protein kinase in airway smooth muscle. , 1997, The American journal of physiology.

[38]  Stephen P. Mayfield,et al.  Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides , 1996, Nature.

[39]  P. Wade,et al.  Regional differences in the number of neurons in the myenteric plexus of the guinea pig small intestine and colon: An evaluation of markers used to count neurons , 1996, The Anatomical record.

[40]  S. E. Brodie New York, New York, USA , 1996 .

[41]  J. Wallace,et al.  Hapten-induced chronic colitis in the rat: alternatives to trinitrobenzene sulfonic acid. , 1995, Journal of pharmacological and toxicological methods.

[42]  L. Buéno,et al.  [Animal models of intestinal inflammation]. , 1995, Gastroenterologie clinique et biologique.

[43]  T. Midtvedt,et al.  Experimental Colitis Induced by Dextran Sulphate in Normal and Germfree Mice , 1994 .

[44]  T. Beresford Marijuana: The Forbidden Medicine , 1993 .

[45]  J. Bakalar,et al.  Marihuana: The Forbidden Medicine , 1993 .

[46]  J. Wallace,et al.  Hapten-induced model of chronic inflammation and ulceration in the rat colon. , 1989, Gastroenterology.

[47]  H. Brill Marihuana: The First Twelve Thousand Years. , 1981, Journal of psychoactive drugs.

[48]  N. Selve Chronic intrajejunal TNBS application in TNBS-sensitized rats: A new model of chronic inflammatory bowel diseases , 2005, Agents and Actions.

[49]  M. Abood Molecular biology of cannabinoid receptors. , 2005, Handbook of experimental pharmacology.

[50]  G. Marsicano,et al.  Cannabinoid receptor type 1 modulates excitatory and inhibitory neurotransmission in mouse colon. , 2004, American journal of physiology. Gastrointestinal and liver physiology.

[51]  T. Bisogno,et al.  Anandamide receptors. , 2002, Prostaglandins, leukotrienes, and essential fatty acids.

[52]  David R. Brown,et al.  Localization of CB1-cannabinoid receptor immunoreactivity in the porcine enteric nervous system , 2000, Cell and Tissue Research.

[53]  U. Holzer‐Petsche,et al.  Tachykinins in the gut. Part II. Roles in neural excitation, secretion and inflammation. , 1997, Pharmacology & therapeutics.

[54]  K. Olden,et al.  The functional gastrointestinal disorders , 1997 .

[55]  D. Drossman,et al.  The Functional Gastrointestinal Disorders: Diagnosis, Pathophysiology, and Treatment : A Multinational Consensus , 1994 .

[56]  W. Stenson,et al.  Quantitative assay for acute intestinal inflammation based on myeloperoxidase activity. Assessment of inflammation in rat and hamster models. , 1984, Gastroenterology.

[57]  R. Christensen,et al.  Cellular and extracellular myeloperoxidase in pyogenic inflammation. , 1982, Blood.